The JV will leverage the dual-arm robot Maholo, developed by Yaskawa subsidiary the Robotic Biology Institute.

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Yaskawa Electric's stock has underperformed due to ongoing destocking in automation and macroeconomic uncertainties, but shares are now relatively inexpensive, making it a potential recovery play.

Astellas Pharma Inc. is setting up a joint venture with Yaskawa Electric Corp. to develop a new cell production platform ...

Based on the memorandum of agreement signed in May, 2024, Astellas and YASKAWA have been advancing discussions toward establishing a joint venture to leverage their mutual strengths and accelerate ...

Astellas Pharma Inc. is setting up a joint venture with Yaskawa Electric Corp. to develop a new cell production platform using Yaskawa’s dual-arm humanoid robot called Maholo. BioWorld BioWorld ...